(Q37327966)

19 August 2017

1 reference

title

Should cannabinoids be used as analgesics for neuropathic pain? (English)

1 reference

19 August 2017

0 references

0 references

Andrew S C Rice

1

1 reference

19 August 2017

publication date

18 November 2008

1 reference

Nature Clinical Practice Neurology

19 August 2017

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

654-655

1 reference

Adverse effects of medical cannabinoids: a systematic review

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Cannabis as a risk factor for psychosis: systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0949

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0949

1 reference

Dimensions Publication ID

19 August 2017

1022532450

0 references

1 reference